A review of the use of modafinil for attention-deficit hyperactivity disorder
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Modafinil (Provigil) is a novel wakefulness-promoting agent that has been shown to have greater efficacy than placebo in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. In particular, three large, drug-company sponsored trials of a film-coated formulation of modafinil (modafinil-ADHD; Sparlon) in children and adolescents with ADHD demonstrated consistent improvements in ADHD symptoms compared with placebo. Mean reductions in symptom ratings (measured using the ADHD-Rating Scale-IV school version questionnaire) ranged from 15.0 to 19.7 (7.3 to 10.1 for placebo). The most common adverse events were insomnia, headache and decreased appetite. Modafinil was generally well tolerated with most side effects considered mild to moderate in severity. Modafinil may have advantages over current therapies for ADHD in that it can be administered once daily and has fewer reinforcing properties than traditional stimulants. Modafinil could potentially be a valuable new treatment option for patients with ADHD. However, rigorous comparative studies with current first-line treatments for ADHD and longer-term independent studies are necessary before modafinil's role in the treatment of ADHD can be fully established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Adler, L. A., Barkley, R., Biederman, J., Conners, C. K., Faraone, S. V., Greenhill, L. L., Jaeger, S., Secnik, K., Spencer, T., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.001 · Cited by 663
BIEDERMAN, J., FARAONE, S., MILBERGER, S., CURTIS, S., CHEN, L., MARRS, A., OUELLETTE, C., MOORE, P., & SPENCER, T. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199603000-00016 · Cited by 510
Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD
Volkow, N. D., & Swanson, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.1909 · Cited by 475
Faraone, S. V., Spencer, T., Aleardi, M., Pagano, C., & Biederman, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000108984.11879.95 · Cited by 404
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391
Gender effects on Attention-Deficit/Hyperactivity disorder in adults, revisited
Biederman, J., Faraone, S. V., Monuteaux, M. C., Bober, M., & Cadogen, E. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.12.003 · Cited by 385
BIEDERMAN, J., FARAONE, S. V., MICK, E., WILLIAMSON, S., WILENS, T. E., SPENCER, T. J., WEBER, W., JETTON, J., KRAUS, I., PERT, J., et al. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199908000-00012 · Cited by 364
A Clinical Perspective of Attention-Deficit/Hyperactivity Disorder Into Adulthood
Wilens, T. E., & Dodson, W. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1003 · Cited by 274
Neural substrates of decision making in adults with attention deficit hyperactivity disorder
Ernst, M., Kimes, A. S., London, E. D., Matochik, J. A., Eldreth, D., Tata, S., Contoreggi, C., Leff, M., & Bolla, K. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.6.1061 · Cited by 254
A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression
DeBattista, C., Lembke, A., Solvason, H. B., Ghebremichael, R., & Poirier, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104910.75206.b9 · Cited by 144
Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder
Turner, D. C., Blackwell, A. D., Dowson, J. H., McLean, A., & Sahakian, B. J. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1993-5 · Cited by 127
Self-citationNon-Stimulant Treatment of Attention-Deficit/Hyperactivity Disorder
Pliszka, S. R. (2003) · CNS Spectrums · doi:10.1017/s1092852900018460 · Cited by 111
Inhibition and Attention Deficit Hyperactivity Disorder in Adults
Ossmann, J. M., & Mulligan, N. W. (2003) · The American Journal of Psychology · doi:10.2307/1423334 · Cited by 75
Cited by
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928
“Atomoxetine is usually considered the second line treatment, followed by other non-stimulants like bupropion, guanfacine, modafinil and tricyclic antidepressents, based on efficacy outcomes in controlled studies in different age groups [239,261-264].”
Eagle, D. M., Bari, A., & Robbins, T. W. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1127-6 · Cited by 548
“From a translational perspective, modafinil similarly improves SSRT in rats and humans (Eagle et al. 2007; Turner 2006; Turner et al. 2003, 2004), effects that are directly comparable with the effects of conventional psychostimulants.”
BackgroundEagle, D. M., Tufft, M. R. A., Goodchild, H. L., & Robbins, T. W. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0701-7 · Cited by 176
Kahbazi, M., Ghoreishi, A., Rahiminejad, F., Mohammadi, M.-R., Kamalipour, A., & Akhondzadeh, S. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.06.024 · Cited by 91
Amiri, S., Mohammadi, M.-R., Mohammadi, M., Nouroozinejad, G.-H., Kahbazi, M., & Akhondzadeh, S. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.025 · Cited by 82
“It has been reported that modafinil causes fewer adverse effects and less dependency potential than methylphenidate and the amphetamines (Ballon and Feifel, 2006; Turner, 2006).”
Background
Metadata
- Authors
- Turner, D.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2006-04
- Volume
- 6
- Issue
- 4
- Pages
- 455-468
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2044303650
- Cited by
- 40
- References
- 13
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.